503 Stock Overview
Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People’s Republic of China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Lansen Pharmaceutical Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.79 |
| 52 Week High | HK$1.82 |
| 52 Week Low | HK$1.20 |
| Beta | 0.92 |
| 1 Month Change | 3.47% |
| 3 Month Change | 5.92% |
| 1 Year Change | 23.58% |
| 3 Year Change | 5.92% |
| 5 Year Change | 101.48% |
| Change since IPO | -59.35% |
Recent News & Updates
Recent updates
Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?
Sep 18
Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?
Mar 27Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet
Sep 27Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Dec 06Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Sep 04We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings
Dec 28
Shareholder Returns
| 503 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0% | -1.9% | -0.5% |
| 1Y | 23.6% | -3.9% | 19.9% |
Return vs Industry: 503 exceeded the Hong Kong Pharmaceuticals industry which returned -10.6% over the past year.
Return vs Market: 503 exceeded the Hong Kong Market which returned -11.4% over the past year.
Price Volatility
| 503 volatility | |
|---|---|
| 503 Average Weekly Movement | 16.3% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 503's share price has been volatile over the past 3 months.
Volatility Over Time: 503's weekly volatility has increased from 10% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 652 | Li Chen | www.lansen.com.cn |
Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People’s Republic of China and Hong Kong. The company operates through Pharmaceuticals, Cosmetics Products, and Healthcare Products segments. It offers Chinese medicine; generic drugs; cosmetic products; and healthcare products.
Lansen Pharmaceutical Holdings Limited Fundamentals Summary
| 503 fundamental statistics | |
|---|---|
| Market cap | HK$750.60m |
| Earnings (TTM) | HK$57.82m |
| Revenue (TTM) | HK$506.62m |
13.0x
P/E Ratio1.5x
P/S RatioIs 503 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 503 income statement (TTM) | |
|---|---|
| Revenue | US$64.95m |
| Cost of Revenue | US$22.05m |
| Gross Profit | US$42.90m |
| Other Expenses | US$35.49m |
| Earnings | US$7.41m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.018 |
| Gross Margin | 66.05% |
| Net Profit Margin | 11.41% |
| Debt/Equity Ratio | 14.2% |
How did 503 perform over the long term?
See historical performance and comparisonDividends
2.7%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/20 04:34 |
| End of Day Share Price | 2023/11/28 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lansen Pharmaceutical Holdings Limited is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Ming Kong | DBS Vickers Research |
| Stephen Wang | KGI Securities Co. Ltd. |
| Hongbo Lu | Piper Sandler Companies |